Loading...
Market
Future acquisition offers for Elixir by end of 2024
3
Resolution / Starting Odds
Yes, from a major healthcare company • 50%
Yes, from a financial or investment firm • 25%
No acquisition offers • 25%
Official press releases from Rite Aid or the acquiring company
Story
Rite Aid Wins $200 Million Dispute Over Elixir Sale After Judge's Monday Ruling
Jun 24, 2024, 06:00 PM
Rite Aid has successfully defeated MedImpact Healthcare Systems in a $200 million dispute over the sale of its pharmacy benefit manager, Elixir. A judge ruled on Monday that MedImpact is not entitled to recoup the $200 million in extra costs, as it assumed Elixir's debts when it acquired the company. This ruling absolves Rite Aid of any responsibility for the additional costs tied to the recent acquisition.
View original story
Similar markets
BlackRock • 25%
MSCI • 25%
Other competitor • 25%
No major acquisition • 25%
Below $500M • 25%
$500M to $1B • 25%
$1B to $2B • 25%
Above $2B • 25%
